newsfilter
← Latest News
Business Wire·

Aptinyx Reports First Quarter 2022 Financial Results and Highlights Recent Clinical Progress

Current cash position of > $100 million expected to fund operations into 2024 and enable readouts from all three ongoing Phase 2 studies Data readout from Phase 2b study of NYX-2925 in fibromyalgia expected in early to mid 3Q 2022 Data readout fro